Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | NQO2 | P16083 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 2/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.32 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | RECQL | P46063 | 2/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6252116 | 0.83 | NQO2 (0.36) | CYP19A1NQO2LMNAKDM4ESOST | |
| SCHEMBL13618322 | 0.77 | RXFP1 (0.34) | KMT2A | |
| SCHEMBL29565868 | 0.76 | CYP19A1 (0.36) | CYP19A1NQO2LMNAKDM4ESOST | |
| SCHEMBL29424759 | 0.76 | CYP19A1 (0.36) | CYP19A1NQO2LMNAKDM4ESOST | |
| SCHEMBL28341 | 0.76 | CYP19A1 (0.36) | CYP19A1NQO2LMNAKDM4ESOST | |
| SCHEMBL30393960 | 0.75 | CYP19A1 (0.35) | CYP19A1NQO2LMNAKDM4ESOST | |
| SCHEMBL7645402 | 0.74 | CYP19A1 (0.34) | CYP19A1NQO2LMNAKDM4ESOST | |
| SCHEMBL18395664 | 0.73 | NQO2 (0.34) | CYP19A1NQO2LMNAKDM4ESOST | |
| SCHEMBL25448348 | 0.72 | CYP19A1 (0.33) | CYP19A1NQO2LMNAKDM4ESOST | |
| SCHEMBL5694508 | 0.72 | PTGS2 (0.44) | LMNAKDM4ECYP1A2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2966054-B1 | METHOD OF PRODUCING OPTICALLY-ACTIVE ALDEHYDE | TAKASAGO PERFUMERY CO LTD (JP) | 2019-01-02 | — | — | EP | disclosed |
| US-9796678-B2 | Method for manufacturing optically active compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-10-24 | — | — | US | disclosed |
| US-20170022162-A1 | METHOD FOR MANUFACTURING OPTICALLY ACTIVE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-01-26 | — | — | US | disclosed |
| US-20160152550-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2,3-DIHYDROFARNESAL | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2016-06-02 | — | — | US | disclosed |
| EP-2966054-A1 | METHOD OF PRODUCING OPTICALLY-ACTIVE ALDEHYDE | Takasago International Corporation (JP) | 2016-01-13 | — | — | EP | disclosed |
| US-20150329452-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ISOPULEGOL AND OPTICALLY ACTIVE MENTHOL | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-11-19 | — | — | US | disclosed |
| EP-2894143-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2,3-DIHYDROFARNESAL | Takasago International Corporation (JP) | 2015-07-15 | — | — | EP | disclosed |
| US-7619003-B2 | Process for producing optically active compound | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2009-11-17 | — | — | US | disclosed |
| EP-1277748-B1 | Process for producing optically active y-Butyrolactone | TAKASAGO PERFUMERY CO LTD (JP) | 2004-04-21 | — | — | EP | disclosed |
| EP-1403262-A1 | Process for producing optically active alpha butyrolactone | Takasago International Corporation (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-6608214-B2 | Hydrogenating optically active 4-substituted oxy-3-hydroxy-butyrate followed by simultaneous deprotection and ring closure; economic and efficient synthesis | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2003-08-19 | — | — | US | disclosed |
| US-20030105341-A1 | Process for producing optically active gamma-butyrolactone | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2003-06-05 | — | — | US | disclosed |
| EP-1277748-A1 | Process for producing optically active y-Butyrolactone | Takasago International Corporation (JP) | 2003-01-22 | — | — | EP | disclosed |
| US-6342644-B1 | MULTISTAGE PROCESS OF HYDROGENATION WITH PHOSPHINE COMPLEX | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329452-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ISOPULEGOL AND OPTICALLY ACTIVE MENTHOL | ACSL3, ACSL6, ALOX5 | CYP19A1 96/4885NQO2 3557/4885LMNA 1516/4885 |
| US-20030105341-A1 | Process for producing optically active gamma-butyrolactone | HSD17B10, HSD17B1, HSD17B12 | CYP19A1 29/4885NQO2 1701/4885LMNA 3152/4885 |
| US-20170022162-A1 | METHOD FOR MANUFACTURING OPTICALLY ACTIVE COMPOUND | C9, C5, PRMT7 | CYP19A1 25/4885NQO2 808/4885LMNA 3744/4885 |
| US-20160152550-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2,3-DIHYDROFARNESAL | FNTB, FNTA, LSS | CYP19A1 1144/4885NQO2 963/4885LMNA 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.